Gaar-Humphreys Karen R, Spanjersberg Talitha C F, Santarelli Giorgia, Grinwis Guy C M, Szatmári Viktor, Roelen Bernard A J, Vink Aryan, van Tintelen J Peter, Asselbergs Folkert W, Fieten Hille, Harakalova Magdalena, van Steenbeek Frank G
Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.
Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht University, 3584 CT Utrecht, The Netherlands.
Animals (Basel). 2022 Jun 29;12(13):1679. doi: 10.3390/ani12131679.
Cardiac disease is a leading cause of death for both humans and dogs. Genetic cardiomyopathies, including dilated cardiomyopathy (DCM), account for a proportion of these cases in both species. Patients may suffer from ventricular enlargement and systolic dysfunction resulting in congestive heart failure and ventricular arrhythmias with high risk for sudden cardiac death. Although canine DCM has similar disease progression and subtypes as in humans, only a few candidate genes have been found to be associated with DCM while the genetic background of human DCM has been more thoroughly studied. Additionally, experimental disease models using induced pluripotent stem cells have been widely adopted in the study of human genetic cardiomyopathy but have not yet been fully adapted for the in-depth study of canine genetic cardiomyopathies. The clinical presentation of DCM is extremely heterogeneous for both species with differences occurring based on sex predisposition, age of onset, and the rate of disease progression. Both genetic predisposition and environmental factors play a role in disease development which are identical in dogs and humans in contrast to other experimental animals. Interestingly, different dog breeds have been shown to develop distinct DCM phenotypes, and this presents a unique opportunity for modeling as there are multiple breed-specific models for DCM with less genetic variance than human DCM. A better understanding of DCM in dogs has the potential for improved selection for breeding and could lead to better overall care and treatment for human and canine DCM patients. At the same time, progress in research made for human DCM can have a positive impact on the care given to dogs affected by DCM. Therefore, this review will analyze the feasibility of canines as a naturally occurring bidirectional disease model for DCM in both species. The histopathology of the myocardium in canine DCM will be evaluated in three different breeds compared to control tissue, and the known genetics that contributes to both canine and human DCM will be summarized. Lastly, the prospect of canine iPSCs as a novel method to uncover the contributions of genetic variants to the pathogenesis of canine DCM will be introduced along with the applications for disease modeling and treatment.
心脏病是人类和犬类死亡的主要原因。遗传性心肌病,包括扩张型心肌病(DCM),在这两个物种的此类病例中占一定比例。患者可能会出现心室扩大和收缩功能障碍,导致充血性心力衰竭和室性心律失常,心脏性猝死风险很高。尽管犬类DCM与人类的疾病进展和亚型相似,但仅发现少数候选基因与DCM相关,而人类DCM的遗传背景已得到更深入的研究。此外,使用诱导多能干细胞的实验性疾病模型已广泛应用于人类遗传性心肌病的研究,但尚未完全适用于犬类遗传性心肌病的深入研究。DCM的临床表现对于这两个物种来说都极其异质,基于性别易感性、发病年龄和疾病进展速度会出现差异。与其他实验动物不同,遗传易感性和环境因素在疾病发展中都起作用,这在犬类和人类中是相同的。有趣的是,不同犬种已被证明会发展出不同的DCM表型,这为建模提供了独特的机会,因为有多种针对DCM的品种特异性模型,其遗传变异比人类DCM少。更好地了解犬类DCM有可能改善育种选择,并可能为人类和犬类DCM患者带来更好的整体护理和治疗。同时,人类DCM的研究进展可能会对受DCM影响的犬类护理产生积极影响。因此,本综述将分析犬类作为这两个物种DCM的天然双向疾病模型的可行性。将与对照组织相比,评估三种不同犬种的犬类DCM心肌组织病理学,并总结导致犬类和人类DCM的已知遗传学。最后,将介绍犬类诱导多能干细胞作为一种揭示遗传变异对犬类DCM发病机制贡献的新方法的前景,以及其在疾病建模和治疗中的应用。